{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:57:50Z","timestamp":1777395470821,"version":"3.51.4"},"reference-count":22,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2022,5,31]]},"abstract":"<jats:p>Background: Diabetes and cardiovascular disease increase the risk of incident cognitive dysfunction. Identification of novel biochemical markers for cognitive dysfunction may identify people at the highest risk while yielding insights regarding the pathophysiology of cognitive dysfunction. Objective: To identify cardiovascular biomarkers in serum that are independent predictors of cognitive dysfunction in individuals with dysglycemia. Methods: This analysis was conducted in 8,365 participants in the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial whose stored serum was analyzed for 238 cardio-metabolic biomarkers and completed a baseline Mini-Mental State Examination (MMSE). Fine and Gray sub distribution hazard models accounting for the competing risk of death accounting for clinical risk factors and the baseline MMSE were used to identify biomarkers that predicted incident cognitive dysfunction (MMSE\u200a&lt;\u200a24 or dementia) using forward selection with an inclusion p-value &lt;\u200a0.0002 to account for multiplicity. Results: During a median follow-up period of 6.2 years, 939 individuals developed cognitive dysfunction. After accounting for 17 clinical risk factors, glargine allocation, and the baseline MMSE, three biomarkers (\u03b1-2 Macroglobulin, HR 1.19; 95% CI 1.12, 1.27; Macrophage Inflammatory Protein 1\u03b1, HR 1.11; 95% CI 1.06, 1.16; and Growth Hormone, HR 0.91; 95% CI 0.87, 0.96) independently predicted incident cognitive dysfunction (p\u200a&lt;\u200a0.0002). Addition of these biomarkers to a model that included clinical risk factors, however, did not improve the ability to predict cognitive dysfunction. Conclusion: Addition of independent biomarkers to clinical risk factors for cognitive dysfunction in people with dysglycemia did not predict incident cognitive dysfunction better than clinical risk factors alone.<\/jats:p>","DOI":"10.3233\/jad-215195","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T10:51:30Z","timestamp":1650019890000},"page":"1143-1150","source":"Crossref","is-referenced-by-count":1,"title":["Biomarkers of Prevalent and Incident Cognitive Dysfunction in People with Dysglycemia: Data from the ORIGIN Trial"],"prefix":"10.1177","volume":"87","author":[{"given":"Tali","family":"Cukierman-Yaffe","sequence":"first","affiliation":[{"name":"Endocrinology Institute, Gertner Institute, Sheba Medical Center, Ramat-Gan, Israel"},{"name":"Epidemiology Department, Sackler School of Medicine, Herceg Institute of Aging, Tel Aviv University, Tel Aviv, Israel"},{"name":"Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun-Fu","family":"Lee","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Pare","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Canada"},{"name":"Thrombosis and Atherosclerosis Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"McQueen","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibylle","family":"Hess","sequence":"additional","affiliation":[{"name":"Sanofi-Aventis Deutschland GmbH, R&D, Translational Medicine & Early Development, Biomarkers & Clinical Bioanalyses, Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hertzel C.","family":"Gerstein","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-215195_ref1","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1007\/s00125-005-0023-4","article-title":"Cognitive decline and dementia in diabetes\u2013systematic overview of prospective observational studies","volume":"48","author":"Cukierman","year":"2005","journal-title":"Diabetologia"},{"key":"10.3233\/JAD-215195_ref2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/dmrr.1112","article-title":"Cognitive dysfunction in patients with type 2 diabetes","volume":"26","author":"Reijmer","year":"2010","journal-title":"Diabetes Metab Res Rev"},{"key":"10.3233\/JAD-215195_ref3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejphar.2013.04.055","article-title":"Sweet memories: 20 years of progress in research on cognitive functioning in diabetes","volume":"719","author":"Biessels","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.3233\/JAD-215195_ref5","first-page":"e47","article-title":"2014 Alzheimer\u2019s disease facts and figures","volume":"10","author":"Alzheimer\u2019s Association","year":"2014","journal-title":"Alzheimers Dementia"},{"key":"10.3233\/JAD-215195_ref6","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1212\/01.WNL.0000140291.86406.D1","article-title":"Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study","volume":"63","author":"Xu","year":"2004","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.3233\/JAD-215195_ref7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1447-0594.2011.00818.x","article-title":"Risk factors associated with cognitive decline in the elderly with type 2 diabetes: pooled logistic analysis of a 6-year observation in the Japanese Elderly Diabetes Intervention Trial","volume":"12","author":"Umegaki","year":"2012","journal-title":"Geriatr Gerontol Int"},{"key":"10.3233\/JAD-215195_ref8","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.2337\/dc12-2241","article-title":"Clinical and subclinical macrovascular disease as predictors of cognitive decline in older patients with Edinburgh type 2 diabetes: the Type 2 Diabetes Study","volume":"36","author":"Feinkohl","year":"2013","journal-title":"Diabetes Care"},{"key":"10.3233\/JAD-215195_ref9","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1161\/CIRCULATIONAHA.115.015744","article-title":"Identifying novel biomarkers for cardiovascular events or death in people with dysglycemia","volume":"132","author":"Gerstein","year":"2015","journal-title":"Circulation"},{"key":"10.3233\/JAD-215195_ref10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Investigators","year":"2012","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-215195_ref11","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S2213-8587(14)70062-2","article-title":"Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial","volume":"2","author":"Cukierman-Yaffe","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.3233\/JAD-215195_ref12","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1532-5415.1992.tb01992.x","article-title":"The mini-mental state examination: a comprehensive review","volume":"40","author":"Tombaugh","year":"1992","journal-title":"J Am Geriatr Soc"},{"key":"10.3233\/JAD-215195_ref13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","journal-title":"J Psychiatr Res"},{"key":"10.3233\/JAD-215195_ref14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S2213-8587(13)70048-2","article-title":"Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: a cohort study","volume":"1","author":"Exalto","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.3233\/JAD-215195_ref16","doi-asserted-by":"crossref","first-page":"795","DOI":"10.7326\/0003-4819-150-11-200906020-00007","article-title":"Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures","volume":"150","author":"Cook","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.3233\/JAD-215195_ref17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0002-9440(10)65542-3","article-title":"Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer\u2019s disease brains","volume":"153","author":"Xia","year":"1998","journal-title":"Am J Pathol"},{"key":"10.3233\/JAD-215195_ref18","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.neurobiolaging.2006.02.013","article-title":"Peripheral T cells overexpress MIP-1alpha to enhance its transendothelial migration in Alzheimer\u2019s disease","volume":"28","author":"Man","year":"2007","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-215195_ref19","doi-asserted-by":"crossref","first-page":"15862","DOI":"10.1038\/srep15862","article-title":"The chemokine MIP-1alpha\/CCL3 impairs mouse hippocampal synaptic transmission, plasticity and memory","volume":"5","author":"Marciniak","year":"2015","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-215195_ref20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/mp.2016.206","article-title":"Alpha-2 macroglobulin in Alzheimer\u2019s disease: a marker of neuronal injury through the RCAN1 pathway","volume":"22","author":"Varma","year":"2017","journal-title":"Mol Psychiatry"},{"key":"10.3233\/JAD-215195_ref21","first-page":"22","article-title":"Levels of alpha-2 macroglobulin in cognitively normal Mexican-Americans with subjective cognitive decline: a HABLE study","volume":"10","author":"Hall","year":"2019","journal-title":"Curr Neurobiol"},{"key":"10.3233\/JAD-215195_ref22","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1212\/WNL.0b013e3181c34b47","article-title":"Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease","volume":"73","author":"Hoops","journal-title":"Neurology"},{"key":"10.3233\/JAD-215195_ref24","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1017\/S1041610212001068","article-title":"The Montreal Cognitive Assessment is superior to the Mini-Mental State Examination in detecting patients at higher risk of dementia","volume":"24","author":"Dong","year":"2012","journal-title":"Int Psychogeriatr"},{"key":"10.3233\/JAD-215195_ref25","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1161\/STROKEAHA.115.010290","article-title":"Methodological Factors in determining risk of dementia after transient ischemic attack and stroke: (III) Applicability of cognitive tests","volume":"46","author":"Pendlebury","year":"2015","journal-title":"Stroke"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-215195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:05:54Z","timestamp":1777370754000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-215195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":22,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jad-215195","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]}}}